Russell Investments Group Ltd. Has $286,000 Stake in ICU Medical, Inc. (NASDAQ:ICUI)

Russell Investments Group Ltd. trimmed its position in shares of ICU Medical, Inc. (NASDAQ:ICUI) by 10.4% during the first quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission. The fund owned 1,731 shares of the medical instruments supplier’s stock after selling 201 shares during the period. Russell Investments Group Ltd.’s holdings in ICU Medical were worth $286,000 as of its most recent filing with the Securities and Exchange Commission.

Other institutional investors have also added to or reduced their stakes in the company. Neuberger Berman Group LLC increased its holdings in ICU Medical by 16.6% during the fourth quarter. Neuberger Berman Group LLC now owns 443,248 shares of the medical instruments supplier’s stock worth $69,803,000 after buying an additional 63,181 shares during the last quarter. JPMorgan Chase & Co. lifted its position in shares of ICU Medical by 1.1% in the fourth quarter. JPMorgan Chase & Co. now owns 754,421 shares of the medical instruments supplier’s stock valued at $118,806,000 after buying an additional 8,256 shares during the last quarter. Van ECK Associates Corp boosted its stake in shares of ICU Medical by 380.0% during the 4th quarter. Van ECK Associates Corp now owns 2,683 shares of the medical instruments supplier’s stock worth $423,000 after acquiring an additional 2,124 shares during the period. Fuller & Thaler Asset Management Inc. increased its holdings in shares of ICU Medical by 7.8% during the 4th quarter. Fuller & Thaler Asset Management Inc. now owns 578,533 shares of the medical instruments supplier’s stock worth $91,107,000 after acquiring an additional 41,756 shares during the last quarter. Finally, Eagle Asset Management Inc. raised its stake in ICU Medical by 0.3% in the 1st quarter. Eagle Asset Management Inc. now owns 65,279 shares of the medical instruments supplier’s stock valued at $10,768,000 after acquiring an additional 186 shares during the period. 91.49% of the stock is currently owned by institutional investors and hedge funds.

Insider Transactions at ICU Medical

In other news, CEO Vivek Jain sold 30,000 shares of the firm’s stock in a transaction that occurred on Wednesday, July 12th. The shares were sold at an average price of $180.02, for a total transaction of $5,400,600.00. Following the transaction, the chief executive officer now directly owns 23,677 shares of the company’s stock, valued at $4,262,333.54. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through the SEC website. In other news, CEO Vivek Jain sold 30,000 shares of the stock in a transaction on Wednesday, July 12th. The stock was sold at an average price of $180.02, for a total transaction of $5,400,600.00. Following the sale, the chief executive officer now directly owns 23,677 shares of the company’s stock, valued at approximately $4,262,333.54. The transaction was disclosed in a legal filing with the SEC, which is accessible through the SEC website. Also, Director Elisha W. Finney sold 194 shares of the stock in a transaction on Wednesday, June 7th. The stock was sold at an average price of $190.41, for a total value of $36,939.54. Following the sale, the director now directly owns 1,481 shares in the company, valued at $281,997.21. The disclosure for this sale can be found here. Over the last 90 days, insiders sold 60,194 shares of company stock valued at $11,097,640. 7.50% of the stock is currently owned by corporate insiders.

ICU Medical Trading Down 0.1 %

Shares of NASDAQ:ICUI opened at $144.86 on Tuesday. ICU Medical, Inc. has a 12-month low of $128.90 and a 12-month high of $212.43. The stock has a market cap of $3.50 billion, a PE ratio of -71.71 and a beta of 0.64. The business has a 50 day moving average of $161.88 and a 200-day moving average of $171.62. The company has a quick ratio of 0.97, a current ratio of 2.57 and a debt-to-equity ratio of 0.76.

ICU Medical (NASDAQ:ICUI) last posted its earnings results on Monday, August 7th. The medical instruments supplier reported $1.58 earnings per share for the quarter, topping analysts’ consensus estimates of $1.15 by $0.43. ICU Medical had a positive return on equity of 6.93% and a negative net margin of 2.11%. The company had revenue of $549.31 million during the quarter, compared to the consensus estimate of $562.90 million. As a group, equities research analysts forecast that ICU Medical, Inc. will post 5.14 earnings per share for the current year.

Analyst Upgrades and Downgrades

A number of equities analysts have commented on the stock. KeyCorp lifted their price objective on shares of ICU Medical from $200.00 to $216.00 in a research report on Tuesday, May 9th. 51job reaffirmed a “maintains” rating on shares of ICU Medical in a report on Tuesday, May 9th. Finally, StockNews.com started coverage on shares of ICU Medical in a report on Thursday, August 17th. They issued a “hold” rating on the stock.

ICU Medical Profile

ICU Medical, Inc, together with its subsidiaries, develops, manufactures, and sells medical devices used in infusion therapy, vascular access, and vital care applications worldwide. Its infusion therapy products include needlefree products under the MicroClave, MicroClave Clear, and NanoClave brands; Neutron catheter patency devices; ChemoClave and ChemoLock closed system transfer devices, which are used to limit the escape of hazardous drugs or vapor concentrations, block the transfer of environmental contaminants into the system, and eliminates the risk of needlestick injury; and ClearGuard HD, that maintains hemodialysis catheters.